Abstract
35. A Herceptin-Based CAR with Modified Signaling Domains Leads to Robust Anti-Tumor Cell Line Activity and Enhanced Survival of Transduced T Lymphocytes
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have